Drug Names And Therapeutic Classes - NAPLEX

Selective serotonin reuptake inhibitor (SSRI). Inhibits serotonin reuptake in synaptic clefts, increasing availability for mood regulation in depression and anxiety disorders.

Inhaled corticosteroid (ICS). Suppresses airway inflammation by inhibiting pro-inflammatory cytokines and immune cell migration in asthma management.

Short-acting beta-2 agonist (SABA). Activates beta-2 adrenergic receptors in bronchial smooth muscle, causing rapid bronchodilation for acute asthma relief.

Thyroid hormone (T4) replacement. Synthetic form of thyroxine that restores euthyroid state by converting to T3 and regulating metabolism in hypothyroidism.

SGLT2 inhibitor. Inhibits sodium-glucose cotransporter 2 in kidneys, promoting glucosuria and improving glycemic control with cardiovascular benefits.

Long-acting basal insulin. Provides steady insulin release mimicking endogenous basal secretion, used for glycemic control in diabetes with low hypoglycemia risk.

Biguanide antihyperglycemic. Decreases hepatic glucose production and improves insulin sensitivity in type 2 diabetes without causing hypoglycemia.

Histamine-2 receptor antagonist (H2RA). Competitively blocks histamine at H2 receptors on parietal cells, reducing basal and stimulated gastric acid secretion.

Proton pump inhibitor (PPI). Irreversibly inhibits H+/K+ ATPase in parietal cells, suppressing gastric acid secretion for ulcer treatment and GERD.

Nitrate antianginal (vasodilator). Releases nitric oxide, causing smooth muscle relaxation and vasodilation to relieve angina by reducing cardiac preload.

Irreversible COX-1 inhibitor antiplatelet (salicylate NSAID). Acetylates and irreversibly inhibits platelet COX-1, reducing thromboxane A2 and preventing aggregation at low doses.

P2Y12 inhibitor antiplatelet. Irreversibly inhibits P2Y12 ADP receptors on platelets, preventing aggregation and used for thrombotic event prevention.

Direct thrombin inhibitor (DOAC). Directly inhibits thrombin (factor IIa), blocking fibrinogen conversion to fibrin for anticoagulation in atrial fibrillation.

Direct factor Xa inhibitor (DOAC). Directly inhibits factor Xa, preventing thrombin generation and clot formation without needing routine monitoring.

Vitamin K antagonist anticoagulant. Inhibits vitamin K-dependent clotting factors (II, VII, IX, X) synthesis in the liver, requiring INR monitoring for anticoagulation.

Cholesterol absorption inhibitor. Selectively inhibits cholesterol absorption at the small intestine brush border, lowering LDL without affecting triglycerides much.

Aldosterone antagonist (potassium-sparing diuretic). Antagonizes mineralocorticoid receptors, promoting sodium excretion while sparing potassium in heart failure and hypertension.

Loop diuretic. Potently inhibits Na+/K+/2Cl- cotransporter in the loop of Henle, leading to significant diuresis for edema and heart failure.

Thiazide diuretic. Inhibits sodium reabsorption in the distal convoluted tubule, promoting diuresis and used primarily for hypertension and edema.

Beta-1 selective beta blocker. Selectively antagonizes beta-1 adrenergic receptors in the heart, reducing heart rate and contractility for cardiovascular conditions.

Dihydropyridine calcium channel blocker. Blocks L-type calcium channels primarily in vascular smooth muscle, causing vasodilation and blood pressure reduction.

Angiotensin II receptor blocker (ARB). Selectively blocks angiotensin II at AT1 receptors, preventing vasoconstriction and aldosterone secretion without affecting bradykinin.

Angiotensin-converting enzyme (ACE) inhibitor. Inhibits the enzyme that converts angiotensin I to II, reducing vasoconstriction and aldosterone release for hypertension management.

GLP-1 receptor agonist. Mimics incretin hormone effects, enhancing insulin secretion, suppressing glucagon, and promoting weight loss in diabetes.